Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Core Insights - The weight-loss drug market is rapidly growing, with investment opportunities in established companies like Eli Lilly and Novo Nordisk, as well as smaller biotech firms like Viking Therapeutics [1][2] Company Overview - Viking Therapeutics is focusing on developing VK2735, a GLP-1 medicine currently in phase 3 clinical trials, which increases the likelihood of approval compared to candidates in earlier stages [5][10] - The company is exploring both subcutaneous and oral formulations of VK2735, aiming to address the challenge of maintaining weight loss after treatment [7][8] Market Potential - As of mid-2025, there are 277 obesity-drug candidates in development, but most are unlikely to receive approval, highlighting the competitive nature of the market [4] - Viking's strong mid-stage results for VK2735 position it favorably within this competitive landscape, potentially leading to significant financial success and stock market returns over the next decade [8] Investment Considerations - Investing in Viking Therapeutics is considered riskier but may offer higher upside potential, with a suggested investment of $5,000 for those with above-average risk tolerance [2][10] - The success of VK2735 in phase 3 trials is critical for the company's future market impact and stock performance [10]